BOULDER, Colo., December 2, 2020 — FonesLife Corporation, a subsidiary of NEC Solution Innovators, Ltd. of Japan, announced today that they will begin offering blood-based health tests built on the SomaLogic SomaScan® Platform to consumers in Japan. The tests, which deliver health-management information based on large-scale measurements of an individual’s blood proteins, are expected to help assess health and promote wellness in Japan’s rapidly aging population. The Tokyo-based FonesLife Corporation was established earlier this year to be the exclusive provider of tests in Japan based on SomaLogic’s SomaSignal™ tests.
SomaLogic’s SomaSignal™ tests were made available to patients and providers in a limited number of US medical practices last year. The tests provide personalized health information by measuring thousands of proteins in a single blood sample and identifying patterns that reflect current health status and future disease risks. FonesLife will provide health guidance and life improvement recommendations based on their versions of these ten SomaSignal™ tests:
- Four-year primary and secondary cardiovascular and cerebrovascular risk prediction
- Liver fat
- Glucose tolerance
- Cardiorespiratory fitness
- Alcohol impact
- Resting energy rate
- Body fat percentage
- Visceral fat
- Lean body mass
With over 28 percent of its population over the age of 65, Japan’s “super-aged” society represents a major healthcare challenge. Providing precise health information together with suggested behavioral modifications is expected to encourage each person to make lifestyle improvements that promote healthy aging.
“The people of Japan are going to be the first outside of the United States to benefit from our transformative technology on a large scale, and we could not be happier,” said Roy Smythe, M.D., chief executive officer of SomaLogic. “Japan will be an example to the world of how to leverage new technology to make life better — in this case maximizing health on a large scale, particularly in an aging population.”
For more information about SomaSignal™ tests and the SomaScan® Platform, please visit www.somalogic.com. The SomaSignal™ tests are developed and their performance characteristics determined by SomaLogic, Inc. They have not been cleared or approved by the US Food and Drug Administration.
Laura S. Mizoue, Ph.D.
SomaLogic seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s precise, proprietary, and personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.